The growing use of PARP inhibitors in multiple malignancies was a topic of great interest at the 2020 Directions in Oncology Pharmacy conference in a session titled PARP Inhibition: Current and Emerging Indications for Use in Ovarian, Breast, Pancreatic, and Prostate Cancers. PARP inhibitors impair cellular DNA base excision repair and trap PARP1 on damaged DNA, leading to obstruction at a replication fork.
Cell death is most successful when PARP inhibitors are combined with other drugs or in patients with genetic mutations targeting DNA repair. Read more . . .